Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation

New treatments are needed for B-cell malignancies persisting after allogeneic hematopoietic stem cell transplantation (alloHSCT). We conducted a clinical trial of allogeneic T cells genetically modified to express a chimeric antigen receptor (CAR) targeting the B-cell antigen CD19. T cells for genet...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Kochenderfer, James N., Dudley, Mark E., Carpenter, Robert O., Kassim, Sadik H., Rose, Jeremy J., Telford, William G., Hakim, Frances T., Halverson, David C., Fowler, Daniel H., Hardy, Nancy M., Mato, Anthony R., Hickstein, Dennis D., Gea-Banacloche, Juan C., Pavletic, Steven Z., Sportes, Claude, Maric, Irina, Feldman, Steven A., Hansen, Brenna G., Wilder, Jennifer S., Blacklock-Schuver, Bazetta, Jena, Bipulendu, Bishop, Michael R., Gress, Ronald E., Rosenberg, Steven A.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2013
Assuntos:
Transplantation
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3862276/
https://ncbi.nlm.nih.gov/pubmed/24055823
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2013-08-519413
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados